Dupixent is the first and only medicine indicated to treat eosinophilic esophagitis in the United States; approval granted more than two months ahead of USFDA’s Priority Review action date
In clinical trials, treatment proved more effective than other therapies evaluated
Company's net income rose by 57.5 percent to 3.291 billion euros in Q1
Business EPS of €1.94, up 20.5% on a reported basis and 16.1% at CER, also benefitting from an improved effective tax rate
An RMAT confers eligibility for accelerated approval and priority review of biologics licensing applications (BLA)
No new studies have been requested
Clinical improvements were consistent across patient subgroups including age, gender, ethnicity, and IL-36 gene mutation status
AMX0035 is an investigational therapy for the treatment of amyotrophic lateral sclerosis (ALS).
APS03118 is a novel innovative drug developed by APS with global independent intellectual property rights for unlimited cancer types
It is the first targeted fluorescent imaging agent that illuminates ovarian cancer intraoperatively, enabling the detection of more cancer for removal
Subscribe To Our Newsletter & Stay Updated
